iNtRON Biotechnology Inc - Asset Resilience Ratio

Latest as of September 2025: 10.90%

iNtRON Biotechnology Inc (048530) has an Asset Resilience Ratio of 10.90% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check iNtRON Biotechnology Inc (048530) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩8.58 Billion

≈ $5.81 Million USD Cash + Short-term Investments

Total Assets

₩78.70 Billion

≈ $53.34 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2024)

This chart shows how iNtRON Biotechnology Inc's Asset Resilience Ratio has changed over time. See 048530 net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down iNtRON Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see iNtRON Biotechnology Inc market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩8.58 Billion	10.9%
Total Liquid Assets	₩8.58 Billion	10.90%

Asset Resilience Insights

Moderate Liquidity: iNtRON Biotechnology Inc has 10.90% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

iNtRON Biotechnology Inc Industry Peers by Asset Resilience Ratio

Compare iNtRON Biotechnology Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for iNtRON Biotechnology Inc (2012–2024)

The table below shows the annual Asset Resilience Ratio data for iNtRON Biotechnology Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	17.85%	₩15.42 Billion ≈ $10.45 Million	₩86.37 Billion ≈ $58.53 Million	-40.14pp
2023-12-31	57.99%	₩57.18 Billion ≈ $38.75 Million	₩98.61 Billion ≈ $66.83 Million	+24.40pp
2022-12-31	33.59%	₩47.35 Billion ≈ $32.09 Million	₩140.96 Billion ≈ $95.53 Million	-20.85pp
2021-12-31	54.44%	₩83.49 Billion ≈ $56.58 Million	₩153.37 Billion ≈ $103.93 Million	-11.37pp
2020-12-31	65.81%	₩66.16 Billion ≈ $44.84 Million	₩100.54 Billion ≈ $68.13 Million	+2.50pp
2019-12-31	63.32%	₩56.37 Billion ≈ $38.20 Million	₩89.03 Billion ≈ $60.34 Million	+24.70pp
2018-12-31	38.62%	₩21.16 Billion ≈ $14.34 Million	₩54.80 Billion ≈ $37.13 Million	-3.16pp
2017-12-31	41.77%	₩19.06 Billion ≈ $12.92 Million	₩45.63 Billion ≈ $30.92 Million	+2.51pp
2016-12-31	39.26%	₩23.40 Billion ≈ $15.86 Million	₩59.61 Billion ≈ $40.39 Million	+29.03pp
2015-12-31	10.23%	₩4.13 Billion ≈ $2.80 Million	₩40.37 Billion ≈ $27.36 Million	-3.92pp
2012-12-31	14.15%	₩2.78 Billion ≈ $1.88 Million	₩19.64 Billion ≈ $13.31 Million	--

pp = percentage points

About iNtRON Biotechnology Inc

KQ:048530 Korea Biotechnology

Market Cap

$59.56 Million

₩87.89 Billion KRW

Market Cap Rank

#21279 Global

#1226 in Korea

Share Price

₩2780.00

Change (1 day)

-1.59%

52-Week Range

₩2555.00 - ₩6650.00

All Time High

₩46250.00